The Impact of the Meningococcal Serogroup C Conjugate Vaccine in Canada Between 2002 and 2012

Abstract

MCCV dramatically reduced the incidence of serogroup C IMD in Canada through both direct and indirect effects. The observation that disease incidence decreased with different schedules suggests that the doses at 12 months (common to all provinces) and adolescence (7 of 8 provinces studied) were critical in achieving disease control.